You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 5,308,620

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,308,620

Title:	Protein nanomatrixes and method of production
Abstract:	The present invention is a novel method of producing a unique device of stable porous and membraneless nanomatrixes for carrying medication for in vivo administration. The present invention method produces the device of stable nanomatrixes by mixing a first type of protein which is hemoglobin, a second type of protein which is albumin, and a solution containing an organic solvent which is an alcohol, where the weight ratio of the first and second type of proteins is within the range of approximately 92.+-.5 to 8.+-.5. This results in a turbid suspension of monodispersed nanomatrixes which are typically larger than 1 micron but less than 4 microns in diameter and stable against aggregation and re-solubilization in hypotonic saline for at least 24 hours. An additional solution containing a biologically active substance may be added before or after the solution containing an organic solvent, such that the biologically active substance is entrapped within or bound on the surfaces of the nanomatrixes.
Inventor(s):	Yen; Richard C. K. (Glendora, CA)
Assignee:	Hemoshpere, Inc. (N/A)
Application Number:	07/959,560
Patent Claims:	1. A composition comprising stable porous and membraneless nanomatrixes for carrying medication for in vivo administration, where the nanomatrixes are typically larger than 1 micron but less than 4 microns in diameter, and stable against aggregation and re-solubilization in hypotonic 0.009% saline for at least 24 hours, the nanomatrixes consisting of hemoglobin and albumin, where the weight ratio of said hemoglobin and albumin is between approximately 57:43 and 92:8. 2. The invention as defined in claim 1 wherein said hemoglobin is human hemoglobin and said albumin is human serum albumin. 3. The invention as defined in claim 1 wherein said hemoglobin is a naturally occurring hemoglobin. 4. The invention as defined in claim 1 wherein said hemoglobin is polymerized hemoglobin. 5. The invention as defined in claim 1 wherein said hemoglobin is pyridoxylated-hemoglobin.

Details for Patent 5,308,620

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2011-05-03
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2011-05-03
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2011-05-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.